Allergan, Molecular Partners eye drug meets main goal in two studies

Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading cause of vision loss among people over 65, met the main goal in two late-stage studies.

from Reuters: Health News https://ift.tt/2munT4D